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Abstract: The rare autosomal dominant Charcot-Marie-Tooth type 2B (CMT2B) is associated with
mutations in the RAB7A gene, involved in the late endocytic pathway. CMT2B is characterized
by predominant sensory loss, ulceromutilating features, with lesser-to-absent motor deficits.
We characterized clinically and genetically a family harboring a novel pathogenic RAB7A variant
and performed structural and functional analysis of the mutant protein. A 39-year-old woman
presented with early-onset walking difficulties, progressive distal muscle wasting and weakness in
lower limbs and only mild sensory signs. Electrophysiology demonstrated an axonal sensorimotor
neuropathy. Nerve biopsy showed a chronic axonal neuropathy with moderate loss of all caliber
myelinated fibers. Next-generation sequencing (NGS) technology revealed in the proband and
in her similarly affected father the novel c.377A>G (p.K126R) heterozygous variant predicted to
be deleterious. The mutation affects the biochemical properties of RAB7 GTPase, causes altered
interaction with peripherin, and inhibition of neurite outgrowth, as for previously reported CMT2B
mutants. However, it also shows differences, particularly in the epidermal growth factor receptor
degradation process. Altogether, our findings indicate that this RAB7A variant is pathogenic and
widens the phenotypic spectrum of CMT2B to include predominantly motor CMT2. Alteration of the
receptor degradation process might explain the different clinical presentations in this family.
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1. Introduction
Autosomal dominant axonal Charcot–Marie–Tooth disease type 2B (CMT2B) largely overlaps
with hereditary sensory-autonomic neuropathies (HSANs) as it is characterized by predominant
sensory loss, high frequency of ulcer formations and amputations, with variable motor deficits [1–10].
Affected patients show severe distal sensory loss particularly for pain and touch, reduced-to-absent
deep tendon reflexes, foot deformities, and sometimes distal wasting and weakness mainly in lower
limbs [1–5,7–10]. The disease typically starts during the second or third decade [10] and runs a slowly
progressive course [11,12]. Males have a higher occurrence of ulcers [4], suggesting a difference in
disease severity according to gender as for HSAN I [13].
CMT2B is caused by heterozygous mutations in RAB7A, with five mutations (L129F, K157N,
N161T/I, V162M) reported in patients from eleven families [1–5,7–10], all displaying the characteristic
ulcero-mutilating phenotype with variable motor involvement (Table 1).
Pathomechanisms, whereby RAB7A mutations lead to CMT2B, are a matter for debate and
investigation. RAB7A, hereafter referred to as RAB7, is a member of the Rab family of small GTPases
involved in the regulation of vesicular trafficking between early endosomes and lysosomes, controlling
transport to the degradative compartments in the endocytic pathway and lysosome biogenesis [14].
RAB7 modulates the Endoplasmic Reticulum (ER) morphology by controlling the ER homeostasis and
ER stress [15]. Crosstalk occurring at mitochondria-lysosome contact sites regulated by Rab7 has also
been recently demonstrated [16].
Although ubiquitously expressed, RAB7 has specific functions in neurons, where it regulates
retrograde axonal trafficking and signaling of neurotrophin receptors, as well as neurite
outgrowth [17,18]. Furthermore, RAB7 regulates cell migration by influencing integrin trafficking and
vimentin assembly [19] and cortical neurons’ migration during development [20].
Interestingly, RAB7 has specific effectors in neurons as co-immunoprecipitates with the
neurotrophin receptor TrkA (Tropomyosin-receptor-kinase A) and interacts directly with the
intermediate filament protein peripherin [18,21]. Therefore, it is not surprising that mutations
in RAB7 cause a disease restricted to neurons, although it is unclear why sensory neurons are so
selectively vulnerable.
Previous biochemical characterization of four CMT2B-causative RAB7 mutants showed increased
dissociation rate constant (Koff,) for nucleotides and lower GTPase activity per binding event [22–24].
Overexpression of these mutant proteins inhibits neurite outgrowth in several cell lines [25,26].
Furthermore, these RAB7 mutant proteins display stronger interaction with some RAB7 effector
proteins, including RILP (RAB-interacting lysosomal protein), required for lysosomal transport towards
the microtubule organizing center (MTOC) by inducing dynein-dynactin motors recruitment [27].
RAB7 and RILP control degradation of the epidermal-growth-factor receptor (EGFR), a member
of the receptor tyrosine-kinase family involved in regulating cell proliferation, survival, differentiation
and migration [28,29]. Importantly, EGF seems also to have important neurotrophic functions [30,31].
Previous experiments on EGFR degradation obtained on cells transiently or stably transfected
with CMT2B-causing RAB7 mutants gave conflicting results: transient expression of these mutants
demonstrated normal or increased EGFR degradation [22,23] while stable transfection revealed
inhibition [32].
Here, we report a family with a novel CMT2B phenotype with motor predominance and absence
of ulcers and mutilations, carrying a novel pathogenic RAB7 variant (c.377A>G, p.K126R) which is
absent in global databases, affects a highly conserved amino-acid in the GTPase domain of Rab7,
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is predicted to be pathogenic by in silico analysis, and is transmitted as an autosomal dominant trait.
We performed extensive biochemical and functional studies, which confirmed its pathogenic role.
Table 1. RAB7A mutations associated with Charcot–Marie–Tooth type 2B (CMT2B).
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2. Materials and Methods
2.1. Patients
We evaluated clinically and electrophysiologically (standard procedures) one healthy and two
affected family members (Figure 1A). Informed consent was obtained for all procedures from
study participants.
The index case underwent a biopsy of sural nerve biopsy which was processed for histological
and ultrastructural examination [33]. 3-mm skin biopsies were taken (from shoulder and the lateral
aspect of the proximal phalanx of the index finger) for fibroblast culture, immunohistochemistry,
and intraepidermal nerve fiber (IENF) count [34].
2.2. Gene Sequence Analysis
The proband’s DNA was analyzed by Next Generation Sequencing (NGS) technology with a
probe-based customized panel for CMT and related disorders (Illumina Nextera Rapid Capture Custom
kit, Illumina Inc., San Diego, CA, USA), (Tables S1–S3). Sequencing was performed using the NGS
MiSeq sequencer (Illumina Inc.). The entire RAB7 gene-targeted region (6 coding exons and 25 bp of
flanking introns) was sequenced by NGS with a depth of coverage >20×. The sequence variant was
confirmed in proband and her father by the Sanger method (Figure 1B).
2.3. Mutagenesis and Plasmid Construction
Most constructs used in this study have been described previously [14,22,29]. RAB7K126R mutant
was constructed using the QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, San Diego,
CA, USA). The oligonucleotides used to generate the mutant were 5′-GTGTTGGGAAACAGGATT
GACCTCG-3′ and 5′-CGAGGTCAATCCTGTTTCCCAACAC-3′. The mutant RAB7K126R plasmids
were obtained using RAB7wt cDNA previously cloned in pcDNA3-2xHA or pET-16b vector in frame
with DNA coding for hemagglutinin (HA) or poly-His tag, respectively.
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2.4. Antibodies
Western blotting analysis (WB): anti-HA (1:500, sc-805), anti-peripherin (1:500, sc-28539) and
anti-vinculin (1:10000, sc-25336) were from Santa Cruz Biotechnology, Santa Cruz, CA, USA; anti-actin
(1:5000, ab-8224) and anti-tubulin (1:6000, clone B512), were from Sigma-Aldrich, St-Louis, MO, USA,
while anti-EGFR (1:2000, 20-ES04) was from Fitzgerald, Concord, MA, USA and anti-RILP (1:400,
13574–1-AP) from Proteintech, Rosemont, IL, USA. Immunofluorescence analysis: anti-early endosome
antigen 1 (EEA1, 1:1000, ab70521, Abcam), anti-HA (1:500, ab9110, Abcam), anti-EGFR (1:100, 20-ES04,
Fitzgerald). Secondary antibodies conjugated to fluorochromes for immunofluorescence or horseradish
peroxidase (HRP) were from Invitrogen (Carlsbad, CA, USA), Santa Cruz Biotechnology or Fitzgerald.
Immunohistochemistry: myelin basic protein (MBP, 1:100, ab7349, Abcam), anti-peripherin (1:1000,
ab4666, Abcam), anti-vasoactive intestinal peptide (VIP, 1:400, ab22736, Abcam), anti-neurofilament
200 (NF-H, 1:400, N0142, Sigma-Aldrich), anti-PGP9.5 (1:500, MCA4750GA, Bio-Rad, Hercules, CA,
USA), anti-EGFR (1:100, 20-ES04, Fitzgerald). Secondary antibodies Alexa Fluor-conjugated (Jackson
ImmunoResearch, Cambridge, UK) were employed.
2.5. Cells and Transfection
Neuro2A and NCI H1299 cells, fibroblasts from CMT2B patients and control were grown
in DMEM supplemented with 10% or 15% FBS, 2 mM L-glutamine, 100 U/mL penicillin and
10 mg/mL streptomycin.
Transfection was performed using Metafectene PRO reagent (Biontex, München, DE) according to
manufacturer’s instructions. Cells were analyzed 24 h after transfection.
2.6. Western Blotting and Co-Immunoprecipitation
Cells were processed for SDS-PAGE and WB as previously described [22]. Frozen sural nerves
were pulverized and sonicated in lysis buffer (95 mM NaCl, 25 mMTris-HCl, pH 7.4, 10 mM EDTA, 2%
SDS, and protease inhibitors) and lysates were subjected to WB [20].
Densitometry analysis was performed using the NIH ImageJ program or Gene Tools from
Syngene and normalized to appropriate loading controls signal intensity. For immunoprecipitation,
we used the anti-HA affinity gel (Ezview Red Anti-HA E6779, Sigma-Aldrich) according to the
manufacturer’s instruction.
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c.377A>G (p.K126R) variant in the RAB7 gene. (C,D) Sural nerve biopsy from the 18-year-old
proband. (C) Semithin section stained with toluidine blue showing a uniform and moderate loss of
fibers. (D) At higher magnification, no degenerating or regenerating fibers were observed. Scale
bars: C = 100 µm; D = 50 µm. Skin biopsies from the 38-year-old proband (E) and a 52-year-old
healthy female individual (F), taken at the medial side of the proximal phalanx of the index finger.
(E,F) Immunostaining with anti-protein gene product 9.5 antibodies (PGP9.5) showed a minimal
reduction of the intraepidermal nerve fiber (IENF) density in the proband (E) as compared to control
(F). Arrows indicate intra-epidermal nerve fibers and arrowheads indicate dermal nerve bundles.
Scale bars: E, F = 50 µm. (G) The CLUSTAL multiple sequence alignment by MUSCLE (3.8) shows
the conservation of lysine amino-acid at position 126 during evolution [35]. (H) In silico analysis:
RAB7K126R variant was predicted to be pathogenic by major online programs.
2.7. Confocal Immunofluorescence Microscopy
Cells grown on 12-mm round glass coverslips were fixed, permeabilized with 0.1% Triton X-100
for 5 min at room temperature and incubated with primary and secondary antibodies as previously
described [21]. Cells were viewed with a Zeiss LSM700 confocal microscope. Zen 2011 software (Carl
Zeiss, Oberkochen, Germany) was used for image capture and to calculate the weighted colocalization
coefficient of EGFR and EEA1.
Skin biopsies were sectioned (50 µm) using a standard cryostat (Bio-Optica, Milan, Italy).
Immunohistochemistry assays were performed following a standard free-floating protocol. Fluorescent
images were acquired with Leica TSC SP8 confocal microscope (Leica Microsystems, Wetzlar, Germany).
2.8. Nucleotide Dissociation and GTPase Assay
Nucleotide exchange assay and determination of Koff were performed as previously reported [36].
The GTPase assay was performed as previously described [37]. GTP hydrolysis was quantified as a
GDP signal relative to GDP+GTP signal [37].
2.9. EGFR Degradation Assay
To measure EGFR degradation cells were treated and processed as previously described [22].
2.10. Neurite Outgrowth Assay
Differentiation of Neuro2A was triggered by serum withdrawal as previously described [25].
Cells were co-transfected with the pEGFPC1 vector (to express GFP and visualize the entire cell) and
with a plasmid for expression of HA-tagged RAB7wt or mutant proteins, fixed, permeabilized and
stained [19]. For each experiment, to determine the percentage of cells bearing neurites (>50 µm),
approximately 100 transfected cells were counted in at least 10 randomly chosen visual fields.
We compared the number of cells bearing neurites longer than 50 µm between control cells and cells
expressing HA-tagged RAB7wt and mutant proteins.
2.11. Real-Time PCR
Total RNA was isolated using the RNeasy Micro kit (Qiagen, Hilden, Germany) and
retrotranscription was made using SuperScript II Reverse Transcriptase (Invitrogen) according to the
manufacturer’s instructions.
Quantitative real-time PCR was carried out with Power SYBR Green (Applied Biosystems,
Foster City, USA) using Applied Biosystems 7900HT Fast Real-time PCR System. The primers used
were GAPDH forward 5′-GGTGGTCTCCTCTGACTTCAACA-3′ and reverse 5′-GTTGCTGTAGCC
AAATTCGTTGT-3′; EGFR forward 5′-GGCAGGAGTCATGGGAGAA-3′ and reverse: 5′-GCGATGG
ACGGGATCTTAG-3′ from Eurofins Genomics (Ebersberg, Germany). The thermal profile used:
1 cycle of 2 min at 50 ◦C; 1 cycle of 10 min at 95 ◦C; 40 cycles of 15 s at 95 ◦C, 1 min at 55 ◦C; 1 cycle of
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15 s at 95 ◦C and 15 s at 60 ◦C. The relative expression level was calculated using the comparative CT
method and expressed as “fold change.” The relative quantification was considered significant when
there was a minimum of two-fold change.
2.12. Molecular Modeling Studies
Wild type RAB7 structure was retrieved from the Protein Data Bank (pdb code 1T91) and
used to generate the model of RAB7K126R protein (Pymol, The PyMOL Molecular Graphics System,
Version 1.2r3pre, Schrödinger, LLC). Molecular dynamics simulations were performed within MOE
(MOE, Chemical Computing Group Inc., Montreal H3A 2R7 Canada).
2.13. Statistical Analysis
Data were statistically analyzed using Student’s t-test or χ2 test (* p < 0.05, ** p < 0.01 and
*** p < 0.001). Experiments were performed at least in triplicate.
3. Results
3.1. Patients
Patients’ clinical features are reported in Table 2.
The proband (III-1) (Figure 1A), a 39-year-old female, at age 14 years started complaining of
calf muscle cramps, progressive walking difficulties, distal muscle wasting and weakness, recurrent
ankle sprains and balance issues. At age 31 years, she underwent bilateral foot surgery for Achilles
tendon lengthening and toes straightening. Afterward, she started wearing ankle-foot orthoses
(AFOs). She reported no symptoms in upper limbs and minimal sensory loss in the feet. Neurological
examination showed steppage gait, mild wasting, and weakness of intrinsic hand muscles (MRC
4+), moderate distal atrophy in lower limbs, severe paresis of toe and foot dorsiflexors (MRC 0),
and moderate foot plantar-flexion weakness (MRC 3). She had mild pinprick sensory loss in the feet,
slightly reduced vibration sense at the great toe, and absent ankle jerks. She had neither ulcers nor
amputations. CMTES was 9/28.
Nerve conduction studies (NCS) showed no motor responses in the peroneal nerves, decreased
compound muscle action potential (CMAP) amplitude in the tibial nerve (0.4 mV), the reduced
amplitude of right ulnar nerve (5.9 µV) sensory action potential (SAP), unobtainable sural nerve
SAP, with normal findings at other examined motor and sensory nerves in upper limbs. Nerve
conduction velocities (NCVs) were preserved. EMG showed severe neurogenic changes in lower limb
distal muscles.
Nerve biopsy (age 18) showed a chronic axonal neuropathy, with moderate and diffuse loss of
myelinated fibers of all calibers (Figure 1C); residual fibers had normal myelin sheaths. There were
no signs of ongoing degeneration or regeneration (Figure 1D). Electron microscopy confirmed the
histologic findings disclosing some collagen pockets or denervated, flattened, Schwann cell processes
indicating loss of unmyelinated fibers.
Skin IENF density (age 38) was 5.9 fibers/mm, showing only a minimal difference (Figure 1E) with
a gender-matched control (6.4 fibers/mm, Figure 1F).
Her father (II-2) (Figure 1A) had symptom onset at age 11 years, manifesting progressive foot-drop
and walking difficulties, with later occurrence of wasting and weakness of hand muscles, difficulties
in doing buttons, and balance loss. He did neither undergo foot surgery nor complain of positive
sensory symptoms. Neurological examination at age 55 years showed pes cavus, ataxic and steppage
gait, positive Romberg sign, moderate hand tremor, severe distal limb wasting and weakness, with
intrinsic hand muscles MRC = 1–2 and complete loss of foot movements, absent ankle jerks, reduced
position sense at the great toes, and vibration sense at the feet. Neither ulcers nor amputations were
present. CMTES was 11/28 and CMTNS 17/36. NCS was consistent with a severe axonal motor-sensory
polyneuropathy: the absence of sensory and motor responses in lower limbs, markedly reduced
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amplitude of the median CMAP (0.1 mV), ulnar (0.8 µV) and radial (4.4 µV) SAPs. He died of acute
leukemia a few months later.
Proband’s aunt (II-1) (Figure 1A) had no history of neuropathy and normal examination and NCS.
The grandparents were reported to have no symptoms and died in their 60s (I-2) or 70s (I-1); the uncle
(II-4) was asymptomatic and refused clinical examination and genetic testing.
3.2. Identification of a Novel RAB7 Mutation Causing CMT2B
NGS analysis revealed a heterozygous missense variant in RAB7, c.377A>G (p.K126R), in proband
and affected father which was absent in the unaffected aunt and the major gene variant databases (Single
Nucleotide Polymorphism database 150, 1000 Genomes, Exome Variant Server, Exome Aggregation
Consortium, Genome Aggregation Database) (Table S2). The variant, confirmed in both patients by
Sanger sequencing (Figure 1B), is located in a highly conserved amino-acid in the GTPase domain
(Figure 1G) and predicted to be deleterious by in silico analysis (Figure 1H).
Table 2. Clinical features of patients.
Patients Proband Father
Age at examination, yrs. 39 55
Onset age/symptoms 14/Cramps,gait difficulties 11/Gait difficulties
Motor symptoms legs Complete footdrop, AFOs Complete footdrop, AFOs
Sensory symptoms legs Slight sensory loss feet N
Proximal/Distal weakness UL −/+- (4+; 4+) −/+ (2;1)
Proximal/Distal weakness LL −/+ (0;3) −/+ (0;0)
Ankle deep tendon reflexes Absent Absent
Pinprick UL/LL Normal/Ankles Normal/Normal
Joint position sense UL/LL Normal/Normal Normal/Toes
Vibration sense UL/LL Normal/Toes Normal/Ankles
Pes cavus N Y
Additional features Mild toenaildystrophy Hand tremor




Motor weakness based on Medical Research Council Scale: upper limb distal weakness assessed by first dorsal
interosseous and abductor pollicis brevis; upper limb proximal weakness assessed by deltoids, biceps brachii and
triceps. Lower limb distal weakness assessed by anterior tibialis and gastrocnemius; lower limb proximal weakness
assessed by iliopsoas and quadriceps muscles. Values are based on the side that gave the worst score. Abbreviations:
AFO = ankle-foot orthosis; UL = upper limbs; LL = lower limbs; N = no; Y = yes; SAP = sensory action potential;
CMTES = Charcot–Marie–Tooth examination score; + = weakness present; - = weakness absent; +- = mild weakness.
3.3. Characterization of the Biochemical Properties of the RAB7K126R Mutant Protein
To study the biochemical properties of the RAB7K126R mutant, we analyzed the dissociation rate
constants (Koff) for GDP and GTP. We bacterially expressed His-tagged RAB7Q67L (a constitutively
active mutant, impaired in GTP hydrolysis that displays nucleotide Koff similar to RAB7wt), RAB7V162M
(a previously characterized CMT2B mutant) and the new RAB7K126R mutant and purified them by
affinity chromatography. Then, we determined the Koff for GDP and GTP measuring radioactivity
loss over time (Figure 2A,B). As expected, RAB7Q67L showed GDP and GTP Koff similar to previously
published data on RAB7wt [22,36] while the RAB7V162M CMT2B mutant protein displayed higher Koff
for both GTP and GDP, as previously reported [22]. Interestingly, also the RAB7K126R, similarly to the
other CMT2B-causing mutant proteins, exhibited Koff values significantly higher for GDP and GTP
(Figure 2A,B).
We also measured GTPase activity per binding event by loading the purified His-tagged RAB7wt,
RAB7Q67L, RAB7V162M and RAB7K126R with 32P-GTP (Figure 2C). The RAB7 estimated hydrolysis rate
constant was consistent with previous reports [22,36]. Moreover, as previously reported, the RAB7Q67L
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and the CMT2B-causing RAB7V162M mutants showed lower GTPase activity [22]. Notably, also the
RAB7K126R showed impaired GTPase activity per binding event similarly to the RAB7V162M mutant
(Figure 2C).
Altogether these data demonstrate that the RAB7K126R mutant displays higher nucleotide Koff
(particularly high for GDP) and impaired GTP hydrolysis per binding event, similarly to previously
analyzed CMT2B-causing mutant proteins [22–24].
3.4. Expression of the RAB7K126R Mutant Inhibits Neurite outgrowth in Neuro2A Cells
To analyze the impact of the RAB7K126R mutant on a neuronal-specific process, we studied the
effect on neurite outgrowth in neuroblastoma Neuro2A cells, which were transfected with the pEGFP
plasmid to visualize the cells and therefore, the neurites. Cells were co-transfected with the HA empty
plasmid (control cells) or with plasmids encoding HA-tagged RAB7wt, RAB7Q67L, RAB7V162M, or
RAB7K126R. After transfection and differentiation, the cells were processed for immunofluorescence
analysis using anti-HA antibodies to identify transfected cells and scored for the presence of neurites
longer than 50 µm (Figure 2D). About 30% of control cells had long neurite after serum withdrawal and
similar values were obtained also in cells overexpressing RAB7wt (Figure 2E). In contrast, as expected,
expression of the RAB7Q67L or RAB7V162M mutant resulted in a strong neurite outgrowth inhibition
(Figure 2E), consistent with previous results [25]. Similarly, RAB7K126R mutant expression considerably
inhibited neurite outgrowth, by about 60% (Figure 2E).
3.5. Analysis of Peripherin and RILP, two known Downstream RAB7 Effectors
RAB7 interacts with peripherin, an intermediate filament protein expressed mainly in peripheral
nerves, and CMT2B-causing mutants display a stronger interaction compared to RAB7wt [21].
Immunohistochemical study for peripherin in association with anti-MBP and anti-NF-H antibodies
showed a markedly increased expression of peripherin and NF-H in the proband compared to a
CMT2A patient (MFN2R94W, axonal neuropathy control) and a healthy control (Figure 3A).
To investigate how the RAB7K126R mutant interacts with the peripherin, we performed a
co-immunoprecipitation experiment (Figure 3B,C). Neuro 2A cells were transfected with the empty
plasmid or with constructs encoding HA-tagged RAB7wt, RAB7K126R, and RAB7V162M and then lysed.
HA-tagged proteins were immunoprecipitated and subjected to WB using anti-HA and anti-peripherin
antibodies. As expected, peripherin was co-immunoprecipitated by HA-tagged RAB7wt (Figure 3B).
The RAB7V162M mutant was able to co-immunoprecipitate peripherin more efficiently, in accordance
with previous data [21]. Similarly, peripherin was more efficiently co-immunoprecipitated by the
RAB7K126R mutant as compared to RAB7wt (Figure 3B–D).
As RAB7, in association with RILP, controls the late endocytic pathway [21], we decided to analyze
RILP abundance in proband’s sural nerve lysate. Similarly to what described for the disease-causing
RAB7N161T mutant in an immunostaining experiment [2], the amount of RILP was reduced by almost
half (Figure 3E).
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of guanine nucleotides from RAB7K126 , RAB7Q67L, and RAB7V162M. Purified proteins were incubated
with [3H]GDP (A) or [3H]GTP (B), then a 100× excess of cold competitor (GDP or GTP) was added and
dissociation of nucleotide was monitored for 1h to calculate Koff. (C) The measure of GTPase activity of
RAB7wt, RAB7K126R, RAB7Q67L, and RAB7V162 purified proteins per binding event. Proteins were
loaded with [32P]GTP and then GTP hydrolysis was monitored during 8 h adding 100× fold excess of
unlabeled GTP. (D,E) To analyze the effect of RAB7K126R on neurite outgrowth, Neuro2A cells were
co-transfected with the indicated HA-tagged RAB7wt and utant expressing constructs and ith the
pEGFPC1 plasmid to visualize entire cell and incubated for 24 h in seru -free ediu to induce cell
differentiation. ( ) onfocal icroscopy images of a field of cells per condition are shown. Scale
bar = 10 µm. (E) Quantification of neurite outgrowth in Neuro2A cells expressing different RAB7wt
and mutant proteins. Neurites were defined as processes longer than 50 µ . e erce ta e of cells
bearing neurites as calculate as the nu ber of cells ith neurites divided by the total nu ber of
cells. e co pared the nu ber of cells bearing neurites longer than 50 µ bet een control cells (cells
transfected with pEGFPC1 and HA e pty plas id) and cells expres ing RAB7wt t t t i .
e show a statistical analysis of thre independent experiments (χ2 test, * p < 0.001).
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Figure 3. Analysis of two RAB7 interactors: peripherin and RAB-interacting lysosomal protein
(RILP). (A) Immunohistochemical staining was performed on skin biopsy section using antibodies
direct to peripherin, neurofilament-200, and MBP (myelinated nervous fibers) in the proband, in a
patient with a mutation in MFN2 (axonal neuropathy), and in a healthy control. Scale bar = 20 µm
in all images. (B) HA-tagged RAB7wt and mutant proteins were expressed in Neuro2A cells, as
indicated, immunoprecipitated with an anti-HA antibody and subjected to WB using anti-peripherin
and anti-HA antibodies. (C) Total extracts of Neuro2A cells, overexpressing the indicated proteins,
were an lyzed using anti-HA and anti-tubulin antibody to evaluat expression levels of the proteins.
(D) Quantifica ion of immu oprecipitat d per pherin. Values are the mean of three independent
experiments ± s.e.m.. The intensities were quantified by d nsitometry, normalized against th amount
of RAB7wt or RAB7K126R, and plotted as a percentage of the intensities obtained using RAB7wt (set to
1). Data were analyzed statistically using Student’s t-test. Values of cells expressing RAB7K126R were
found to be significantly different from the values of cells expressing RAB7wt (* p < 0.05). (E) Lysates of
the sural nerve from a healthy individual (CTRL) and proband carrying the RAB7K126R mutation were
analyzed by immunoblotting using anti-RILP and anti-actin antibodies. The intensities of the RILP
bands were quantified using Gene Tools from Syngene and normalized against actin. The intensity of
the RILP band in CTRL cells has been set to 1. Data represent the mean ± s.e.m. of six independent
experiments. Statistical analysis was performed using Student’s t-test. *** p < 0.001.
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3.6. Expression of the RAB7K126R Mutant Inhibits Ligand-Induced EGFR Degradation
To establish if the RAB7K126R mutant affects EGFR degradation, a cellular process normally
regulated by RAB7 [28] (Figure S1), we performed an EGFR degradation assay (Figure 4A).
Quantification revealed that, in agreement with previous data [22,23], about 60% of EGFR was
degraded in control cells and in cells expressing RAB7wt (Figure 4A). In contrast, the expression of
RAB7K126R strongly inhibited degradation that was significantly different from RAB7wt (Figure 4A).
Thus, with respect to EGFR degradation, the RAB7K126R seems to behave differently from the previously
discovered CMT2B-causative mutant proteins as a transient expression of these mutants increased
EGFR degradation [22,23].
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set to 1. The error bars represent the s.e.m. of three independent experiments. According to a Student’s
t-test, * p < 0.05; ** p < 0.01. (B) Lysates of dermal fibroblasts from a healthy individual (CTRL) and
CMT2B patients carrying the RAB7K126R mutation were analyzed by immunoblotting using anti-EGFR
and anti-tubulin antibodies. The intensities of the EGFR bands were quantified using NIH ImageJ and
normalized against tubulin. The intensity of the EGFR band in CTRL cells has been set to 1. Data
represent the mean ± s.e.m. of six experiments. Student’s t-test, *** p < 0.001. (C) Fibroblasts derived
from control and CMT2B patients were incubated with cycloheximide and stimulated with EGF for
the indicated times. Cell lysates were analyzed by immunoblotting with antibodies against EGFR
and tubulin. Densitometric analysis was performed with NIH ImageJ normalizing against tubulin.
Data represent the mean ± s.e.m. of at least three experiments. Student’s t-test, * p < 0.05; ** p < 0.01.
(D) Dermal fibroblasts from CTRL and the CMT2B proband carrying the RAB7K126R mutation incubated
with cycloheximide and stimulated with EGF for 3 h were subjected to immunofluorescence analysis
using specific anti-EGFR (green) and anti-EEA1 (red) antibodies followed by the appropriate secondary
antibodies. Scale bar = 20 µm. (E) Data represent the mean ± s.e.m. of at least 50 cells of three
independent experiments. Statistical analyses were performed using Student’s t-test with control
fibroblasts as a referring sample. *** p < 0.001.
3.7. EGFR Amount, Degradation and Intracellular Distribution are Altered in Patient Fibroblasts Carrying the
RAB7K126R Mutation
To validate data obtained by transiently expressing the CMT2B-causing RAB7 mutant proteins we
performed the assay in skin fibroblasts from the proband and a control. We evaluated first the total
EGFR amount in the absence of EGF stimulation. Interestingly, in fibroblasts carrying the RAB7K126R
mutation the amount of EGFR was higher compared to control cells (Figure 4B), while EGFR transcript
quantification by RT-PCR revealed no significant change in EGFR mRNA levels (data not shown),
thus suggesting a difference in EGFR degradation. Therefore, we performed an EGFR degradation
assay and, notably, we found that EGFR degradation was strongly inhibited in fibroblasts carrying
the RAB7K126R mutation as compared to control cells (Figure 4C). In contrast, EGFR degradation was
increased in fibroblasts carrying the V162M mutation (Figure 4C), consistently with previous data [22].
Altogether, these data suggest that the accumulation of EGFR in RAB7K126R is mainly due to
impaired protein degradation.
To determine whether the impaired EGFR degradation is due to trafficking alteration we performed
immunofluorescence analysis of patient and control fibroblasts using specific antibodies against EGFR
and a marker of the early endosomes EEA1 (Figure 4D). Interestingly, EGFR intracellular distribution
differed between control and patient cells: in patient cells, the amount of EGFR colocalizing with
EEA1 was strongly increased, suggesting impaired trafficking of EGFR to late endocytic organelles
(Figure 4E).
3.8. EGFR Amount is Altered in Patient Tissues
We performed WB of sural nerve lysates from the proband and a gender-matched healthy control
and we found an almost twofold increase in EGFR expression (Figure 5A), in agreement with in vitro
results. EGFR expression was also studied in skin biopsy sections: a qualitative analysis of confocal
images, stained using antibodies against EGFR, PGP9.5 (pan-axonal marker), and VIP (sympathetic
cholinergic fibers’ marker), showed a widespread receptor overexpression in the proband, including
areas around nerve fibers (Figure 5B).
Cells 2020, 9, 1028 14 of 21
Cells 2020, 9, x FOR PEER REVIEW 14 of 21 
 
 
Figure 5. Expression of EGFR in proband sural nerve and skin biopsy sections. (A) Sural nerves from 
the proband and a gender-matched healthy control were lysed and EGFR protein expression was 
analyzed in both samples by WB using a specific anti-EGFR antibody. Antibody against vinculin was 
employed as a loading control. Densitometric analysis was performed with Gene Tools from Syngene. 
Data represent the mean ± s.e.m. of four experiments. The intensity of the EGFR band in CTRL cells 
has been set to 1. Statistical analysis was performed using Student’s t-test.* p < 0.05. (B) Confocal 
microscopy study of a skin biopsy from the proband and a healthy control using a specific anti-EGFR 
antibody. Nervous fibers are labeled with PGP9.5 (pan-axonal marker) and VIP (sympathetic 
cholinergic fibers’ marker) antibodies. Scale bar = 20 μm in all images. 
Figure 5. Expression of E FR in proband sural nerve and skin biopsy sections. (A) Sural nerves
from the proband and a gender-matched healthy control were lysed and EGFR protein expression
was analyzed in both samples by WB using a specific anti-EGFR antibody. Antibody against vinculin
was employed as a loading control. Densitometric analysis was performed with Gene Tools from
Syngene. Data represent the mean ± s.e.m. of four experiments. The intensity of the EGFR band
in CTRL cells has been set to 1. Statistical analysis was performed using Student’s t-test. * p < 0.05.
(B) Confocal microscopy study of a skin biopsy from the proband and a healthy control using a specific
anti-EGFR antibody. Nervous fibers are labeled with PGP9.5 (pan-axonal marker) and VIP (sympathetic
cholinergic fibers’ marker) antibodies. Scale bar = 20 µm in all images.
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3.9. RAB7K126R Computational Model
Residue 126 is located in the GTPase binding site, where the lysine side chain forms two H-bonds
with the nucleotide. The first H-bond is made with the ribose ring oxygen, while the second one is an
H-bond bridging the amino group with the hydroxyl group on position 4 of the sugar, via a conserved
water molecule (Figure 6A). Interestingly, this H-bond bridge involves glycine 28 too, contributing to
stabilize not only GTP inside its pocket but also the pocket secondary structure. According to the 3D
model, the arginine side chain is unable to perform this H-bonds network, being differently oriented
due to the bigger volume of its terminal guanidine group. Thus, RAB7K126R mutation, as previously
reported,33 seems to reduce the GTP anchoring inside the protein and consequently to determine an
impaired RAB7 functionality. Short molecular dynamics simulations performed on both wild type and
mutated GTP bound complexes confirm these observations (Figure 6B,C).
Cells 2020, 9, x FOR PEER REVIEW 15 of 21 
 
3.9. RAB7K126R Computational Model 
Residue 126 is located in the GTPase binding site, where the lysine side chain forms two H-bonds 
with the nucleotide. The first H-bond is made with the ribose ring xyge , while the second one is an 
H-b nd bridgin  th  amino group with the hydroxyl group on position 4 of the sugar, via a served 
water molecule (Figure 6A). Interestingly, this H-bond bridg  involves glycine 28 too, contributing 
to stabilize not only GTP inside its pocket but also the pocket secondary structure. According to the 
3D model, the arginine side chain is unable to perform this H-bonds network, being differently 
oriented due to the bigger volume of its terminal guanidine group. Thus, RAB7K126R mutation, as 
previously reported,33 seems to reduce the GTP anchoring inside the protein and consequently to 
determine an impaired RAB7 functionality. Short molecular dynamics simulations performed on 
both wild type and mutated GTP bound complexes confirm these observations (Figure 6B,C). 
 
Figure 6. Structural insights into the disease-causing RAB7K126R mutant. (A) Comparison between the 
wild type (pdb code 1T91) and the virtual model of the mutated protein, colored in light brown and 
light pink, respectively. The RAB7K126R mutation is located in the GTPase domain. (B,C) The H-bond 
interactions performed by K126 (B) or R126 (C), GTP, a conserved water molecule and G28. The 
protein is colored in light brown (B) or light pink (C). Bold dashed blue lines highlight the specific H 
bond net performed by residue 126, GTP, G28, and water. Light blue lines indicate H-bonds. 
Magnesium ion is represented as a green sphere and water molecules are represented as red spheres. 
Figure 6. Struct ral insights into the disease-ca si g B7K126R mutant. (A) Comparison between the
wild type (pdb code 1T91) and the virtual model of the mutated protein, colored in light brown and
light pink, respectively. The RAB7K126R mutation is located in the GTPase domain. (B,C) The H-bond
interactions performed by K126 (B) or R126 (C), GTP, a conserved water molecule and G28. The protein
is colored in light brown (B) or light pink (C). Bold dashed blue lines highlight the specific H bond net
performed by residue 126, GTP, G28, and water. Light blue lines indicate H-bonds. Magnesium ion is
represented as a green sphere and water molecules are represented as red spheres.
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4. Discussion
CMT2B has long been considered mainly a sensory neuropathy with a large overlap with the
HSANs. Only five RAB7 mutations have been reported, all involving the GTP binding domain and
associated with a mainly sensory phenotype.
We identified and characterized a novel missense variant (p.K126R) in RAB7 associated with
predominantly motor CMT2 in the two affected family members. Notably, both subjects had remarkable
muscle wasting and weakness with only minor sensory signs, in keeping with CMT2 with motor
predominance, never linked previously to RAB7 mutations. All previous families showed ulcers and
amputations, with variable motor involvement (Table 1). Lower occurrence of ulcers is reported in
CMT2B females [4], but the motor predominant phenotype was shown also by the father, ruling out a
gender effect.
The p.K126R variant affects, like the other CMT2B mutations, the RAB7 GTP-binding domain
and its pathogenicity is supported by the involved site, segregation analysis, and in silico predictions.
The lysine 126 is very conserved not only in RAB7 during evolution (Figure 1G) but also in many other
GTPases as this amino-acid is part of the switch II region; it is one of the amino-acids forming the
guanine binding pocket and it is a crucial amino-acid residue involved in the hydrogen bond with
the nucleotide ribose oxygen [38]. Importantly, mutations in this amino-acid residue are predicted
to have an increased rate of dissociation of the nucleotides favoring the active GTP-bound state [38].
Despite arginine shares with lysine basic and charged features, it impairs the GTP pocket architecture.
The bulkier side chain of arginine exceeds lysine volume and is thus unable to perform the same
specific interactions with GTP and some amino acid residues (water bridging with glycine 28) in the
surrounding pocket (Figure 6B,C).
We carried out a series of functional experiments to demonstrate the RAB7K126R pathogenic role
and look for differences with other RAB7 mutants, to explain the distinctive predominantly motor
phenotype. Our studies confirmed that the mutation affects a series of RAB7 properties, very similar to
previously characterized mutants, but with at least one important difference.
First, biochemical data indicate that the mutant protein has an increased Koff for both nucleotides
and particularly high for GDP (Figure 2A), inhibiting also GTPase activity per binding event (Figure 2C),
similarly to previous uncovered CMT2B-causing RAB7 mutant proteins [22–24]. Interestingly, the
corresponding mutation in the HRAS gene, a gene encoding a member of the RAS superfamily of small
GTPases as the RAB7 gene, is associated with the Costello syndrome, a disease causing an increased
risk of developing tumors in different organs further supporting pathogenicity of this variant [39].
Second, expression of RAB7K126R strongly inhibits neurite outgrowth, compared to the other
CMT2B-causing RAB7 mutants (Figure 2D) [25,26]. As the onset of CMT2B occurs in the second or
third decade, similarly to many other CMT types, development appears to be unaffected. However, the
mutant proteins can rather impact on axonal regeneration, considering that this process recapitulates
all the stages of neuronal differentiation [40]. Indeed, the detrimental action of RAB7 mutants could
be counteracted by other factors during development, but with age, these factors could become less
effective and a decrease in regeneration capabilities may contribute to the progressive axonal loss
underlying clinical manifestations.
Third, the RAB7K126R mutant protein interacts more strongly with the intermediate filament
peripherin (Figure 3B–D), as for already reported RAB7 mutations. Peripherin is important for neuronal
morphology, maturation, and differentiation, but also axonal regeneration [41,42]. RAB7 affects
peripherin assembly [21] and altered RAB7-peripherin interaction could impair axonal regeneration
thus contributing to nerve degeneration. Notably, we found increased labeling of peripherin in skin
biopsy where numerous peripherin-positive filamentous structures were seen in contrast to the few
seen in controls (Figure 3A).
With respect to both findings, it is noteworthy that the nerve biopsy showed—at least for this
single sensory nerve—no evidence of regenerating clusters despite the moderate loss of myelinated
fibers (Figure 1D).
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Fourth, RAB7K126R mutant protein strongly reduces RILP downstream effector levels (Figure 3E),
similarly to RAB7N161T [2]. Notably, in previous functional studies, siRNA-mediated RILP depletion
was sufficient to cause strong effects on EGFR degradation and the biogenesis of late endosomes [27,43].
Fifth, our data demonstrate also that expression of the RAB7K126R mutant protein causes inhibition
of EGFR degradation in contrast to previously studied CMT2B-RAB7 mutants [22,23]. Indeed,
expression of the RAB7L129F, RAB7K157N, RAB7N161T, and RAB7V162M mutants did not reveal any
inhibition of EGFR degradation but rather a small and reproducible, though not statistically significant,
increase [22,23]. Furthermore, analysis of EGFR degradation in RAB7V162M fibroblasts revealed
an increase of EGFR degradation compared to control fibroblasts (Figure 4C), while, expression of
RAB7K126R caused EGFR degradation inhibition (Figure 4A), which was further confirmed in patient
fibroblasts (Figure 4C). In addition, the total EGFR amount was strongly increased in the RAB7K126R
patient compared to control fibroblasts (Figure 4B). These findings were confirmed by WB on the
sural nerve (Figure 5A) and immunohistochemistry on skin biopsy which showed increased EGFR
staining in the proband compared to the control although primarily in the surround of nerve fibers
(Figure 5B). Three hours after internalization most of EGFR was still in early endosomes in patient cells,
demonstrating that impaired EGFR trafficking to late endosomes and lysosomes causes inhibition of
degradation and accumulation of EGFR (Figure 4D,E).
It is tempting to speculate that the prominent motor symptoms observed in our patients might
be related to the differences in EGFR amount and degradation rate in contrast with previously
studied CMT2B mutants associated with the typical sensory-predominant phenotype. EGF signaling
mediated by EGFR is important for development and maintenance of various tissues including the
nervous system, and EGFR is expressed in differentiated post-mitotic neurons suggesting pleiotropic
functions, although the possibility for this receptor to exert distinct actions on different kind of
neurons (e.g., motor versus sensory) is still unclear. Besides its key role in regulating neural stem cell
proliferation, self-renewal, differentiation, and migration, EGF has neurotrophic and neuromodulatory
functions on different kinds of neurons, increasing neuronal survival [31]. EGFR signaling is also
required for proper cutaneous innervation during development and it seems to limit axonal outgrowth
and branching [44]. Interestingly, after central nervous system (CNS) injuries and diseases, activation of
the EGFR pathway triggers quiescent astrocytes to become reactive and destructive to neurons [45,46].
After spinal cord injury, EGFR activates astrocytes that represent a physical barrier to axon regeneration,
expressing and secreting molecules that inhibit nerve growth [47]. Consistently, rats subjected to
weight-drop spinal cord injury treated with a potent EGFR inhibitor to the injured area show motor
and sensory function improvement [48]. Lack of EGFR expression is associated with progressive
neurodegenerative disorders in mice [49,50]. Overexpression of EGFR is associated with cancer
(high-grade glioma) [51]. Moreover, EGFR has a crucial role in the neurometabolic axis seen in the
aging process [52]. Glia and endothelial cells demonstrate induced expression of EGFR after an acute
injury or chronic neurodegeneration and there are multiple and mechanistically diverse routes by which
the EGFR may be involved in the neuronal aspect of aging-related disorders and neurodegeneration.
Consistently, it has been demonstrated that inhibition of EGFR enhances peripheral nerve regeneration
after injury [30,53,54].
Thus, the inhibited degradation and the consequent accumulation of EGFR observed in RAB7K126R
cells could cause an increase in EGFR signaling leading to inhibition of axonal regeneration.
The above-mentioned absence of nerve regeneration at nerve biopsy in our patient is of interest
in this context.
EGFR has also been implicated in the expansion of the peripheral nervous system (PNS) progenitor
cells, including Schwann cell precursors [55]. After peripheral nerve injury, EGFR expression is
upregulated and promotes proliferation and migration of Schwann cells [56]. Importantly, EGFR
hyperactivation induces a peripheral neurodegenerative disease as transgenic mice overexpressing the
EGFR ligand epigen show a phenotype similar to CMT1A and CMT4F animal models [57].
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Although there are at present no data regarding a specific role of EGFR in motoneurons, literature
data on EGF signaling and EGFR in both CNS and PNS, suggest that the inhibition of EGFR degradation
could be a possible explanation for the different clinical presentation in our family compared to the
previously studied CMT2B families.
Recently, Wong et al. showed a role for RAB7 in driving the interactions between lysosomes and
mitochondria, opening a new field of investigations for unraveling RAB7 functions [16]. We did not
find any evidence of mitochondrial abnormalities in the proband’s sural nerve, but it will be interesting
to study the role of mitochondria in CMT2B in the future and to verify whether these organelles play a
key role in the phenotype and its variants.
5. Conclusions
We demonstrated that the behavior of the RAB7K126R protein was similar to the previously studied
CMT2B-causative RAB7 mutated proteins in all investigated functions except EGFR degradation,
as RAB7K126R showed inhibited degradation of the receptor. It is tempting to speculate that such
difference might explain the distinctive clinical presentation in this family, but further studies are
needed. This report expands the phenotypic spectrum of CMT2B: RAB7 has to be added to the list of
genes causing the classic CMT2 phenotype with motor predominance and must be considered in the
genetic work-up of these patients.
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